Furthermore, phase 3 studies have shown early promise for C3 inhibitors and factor D and factor B inhibitors in PNH patients treated with C5 inhibitors, which are more potent and narrowly selective than pegcetacoplan. Here, C3 is linked to paroxysmal nocturnal hemoglobinuria.